Subtype-specific transcription factors are clinically relevant and show distinct therapeutic vulnerabilities in human small cell lung cancer
C. Lang (Vienna, Austria), Z. Megyesfalvi (Budapest, Hungary), B. Szeitz (Budapest, Hungary), A. Lantos (Budapest, Hungary), N. Woldmar (Lund, Sweden), Z. Valko (budapest, Hungary), A. Schwendenwein (Vienna, Austria), F. Oberndorfer (Vienna, Austria), N. Barany (Budapest, Hungary), S. Paku (Budapest, Hungary), V. Laszlo (Vienna, Austria), H. Kiss (Budapest, Hungary), E. Bugyik (Budapest, Hungary), B. Ferencz (Budapest, Hungary), K. Dezso (Budapest, Hungary), Z. Lohinai (Budapest, Hungary), J. Moldvay (Budapest, Hungary), J. Fillinger (Budapest, Hungary), G. Galffy (Budapest, Hungary), C. Rivard (Colorado, United States), F. Hirsch (Colorado, United States), L. Brcic (Graz, Austria), H. Popper (Graz, Austria), I. Kern (Golnik, Slovenia), M. Kovacevic (Golnik, Slovenia), J. Skarda (Olomouc / Ostrava, Czech Republic), M. Mittak (Olomouc / Ostrava, Czech Republic), A. Szasz (Budapest, Hungary), L. Pizzatti (Rio de Janeiro, Brazil), K. Bogos (Budapest, Hungary), M. Hoda (Vienna, Austria), K. Hoetzenecker (Vienna, Austria), G. Marko-Varga (Lund, Sweden), P. Horvatovics (Groningner, Netherlands), F. Renyi-Vamos (Budapest, Hungary), T. Klikovits (Vienna, Austria), K. Schelch (Vienna, Austria), M. Rezeli (Lund, Sweden), B. Döme (Budapest, Hungary)
Source: International Congress 2022 – Biomarkers and beyond in lung cancer
Session: Biomarkers and beyond in lung cancer
Session type: Oral Presentation
Number: 1383
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Lang (Vienna, Austria), Z. Megyesfalvi (Budapest, Hungary), B. Szeitz (Budapest, Hungary), A. Lantos (Budapest, Hungary), N. Woldmar (Lund, Sweden), Z. Valko (budapest, Hungary), A. Schwendenwein (Vienna, Austria), F. Oberndorfer (Vienna, Austria), N. Barany (Budapest, Hungary), S. Paku (Budapest, Hungary), V. Laszlo (Vienna, Austria), H. Kiss (Budapest, Hungary), E. Bugyik (Budapest, Hungary), B. Ferencz (Budapest, Hungary), K. Dezso (Budapest, Hungary), Z. Lohinai (Budapest, Hungary), J. Moldvay (Budapest, Hungary), J. Fillinger (Budapest, Hungary), G. Galffy (Budapest, Hungary), C. Rivard (Colorado, United States), F. Hirsch (Colorado, United States), L. Brcic (Graz, Austria), H. Popper (Graz, Austria), I. Kern (Golnik, Slovenia), M. Kovacevic (Golnik, Slovenia), J. Skarda (Olomouc / Ostrava, Czech Republic), M. Mittak (Olomouc / Ostrava, Czech Republic), A. Szasz (Budapest, Hungary), L. Pizzatti (Rio de Janeiro, Brazil), K. Bogos (Budapest, Hungary), M. Hoda (Vienna, Austria), K. Hoetzenecker (Vienna, Austria), G. Marko-Varga (Lund, Sweden), P. Horvatovics (Groningner, Netherlands), F. Renyi-Vamos (Budapest, Hungary), T. Klikovits (Vienna, Austria), K. Schelch (Vienna, Austria), M. Rezeli (Lund, Sweden), B. Döme (Budapest, Hungary). Subtype-specific transcription factors are clinically relevant and show distinct therapeutic vulnerabilities in human small cell lung cancer. 1383
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|